FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046711385> ?p ?o ?g. }

• W3046711385 endingPage "153298" @default.
• W3046711385 startingPage "153298" @default.
• W3046711385 abstract "Background: Idiopathic Pulmonary Fibrosis (IPF) is a progressive inflammatory disorder driven by a fibrotic cascade of events such as epithelial to mesenchymal transition, extracellular matrix production and collagen formation in the lungs in a sequential manner. IPF incidences were raising rapidly across the world. FDA approved pirfenidone and nintedanib (tyrosine kinase inhibitors) are being used as a first-line treatment drugs for IPF, however, neither the quality of life nor survival rates have been improved because of patient noncompliance due to multiple side effects. Thus, the development of novel therapeutic approaches targeting TGF-β mediated cascade of fibrotic events is urgently needed to improve the survival of the patients suffering from devastating disease. Purpose: The aim of this study was to investigate and validate the anti-fibrotic properties of Biochanin-A (isoflavone) against TGF-β mediated fibrosis in in vitro, ex vivo, in vivo models and to determine the molecular mechanisms that mediate these anti-fibrotic effects. Methods: The therapeutic activity of BCA was determined in in vitro/ex vivo models. Cells were pre-treated with BCA and incubated in presence or absence of recombinant-TGF-β to stimulate the fibrotic cascade of events. Pulmonary fibrosis was developed by intratracheal administration of bleomycin in rats. BCA treatment was given for 14 days from post bleomycin instillation and then various investigations (collagen content, fibrosis gene/protein expression and histopathological changes) were performed to assess the anti-fibrotic activity of BCA. Results: In vitro/ex vivo (Primary normal, IPF cell line and primary IPF cells/ Precision cut mouse lung slices) experiments revealed that, BCA treatment significantly (p < 0.001) reduced the expression of TGF-β modulated fibrotic genes/protein expressions (including their functions) which are involved in the cascade of fibrotic events. BCA treatment significantly (p < 0.01) reduced the bleomycin-induced inflammatory cell-infiltration, inflammatory markers expression, collagen deposition and expression of fibrotic markers in lung tissues equivalent or better than pirfenidone treatment. In addition, BCA treatment significantly (p < 0.001) attenuated the TGF-β1/BLM-mediated increase of TGF-β/Smad2/3 phosphorylation and resulted in the reduction of pathological abnormalities in lung tissues determined by histopathology observations. Conclusion: Collectively, BCA treatment demonstrated the remarkable therapeutic effects on TGF-β/BLM mediated pulmonary fibrosis using IPF cells and rodent models. This current study may offer a novel treatment approach to halt and may be even rescue the devastating lung scarring of IPF." @default.
• W3046711385 created "2020-08-07" @default.
• W3046711385 creator A5013337556 @default.
• W3046711385 creator A5049280812 @default.
• W3046711385 creator A5053877940 @default.
• W3046711385 creator A5056555947 @default.
• W3046711385 creator A5075729887 @default.
• W3046711385 date "2020-11-01" @default.
• W3046711385 modified "2023-10-05" @default.
• W3046711385 title "Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems" @default.
• W3046711385 cites W1961536135 @default.
• W3046711385 cites W1971817485 @default.
• W3046711385 cites W1981999470 @default.
• W3046711385 cites W1991361883 @default.
• W3046711385 cites W1995053750 @default.
• W3046711385 cites W2002473658 @default.
• W3046711385 cites W2007833225 @default.
• W3046711385 cites W2014475655 @default.
• W3046711385 cites W2019119805 @default.
• W3046711385 cites W2047380457 @default.
• W3046711385 cites W2060276188 @default.
• W3046711385 cites W2075400164 @default.
• W3046711385 cites W2076941943 @default.
• W3046711385 cites W2084926647 @default.
• W3046711385 cites W2092173424 @default.
• W3046711385 cites W2108925801 @default.
• W3046711385 cites W2112996747 @default.
• W3046711385 cites W2114054457 @default.
• W3046711385 cites W2375287196 @default.
• W3046711385 cites W2474397968 @default.
• W3046711385 cites W2475260528 @default.
• W3046711385 cites W2549216037 @default.
• W3046711385 cites W2599075603 @default.
• W3046711385 cites W2623449852 @default.
• W3046711385 cites W2748906750 @default.
• W3046711385 cites W2765757148 @default.
• W3046711385 cites W2765981651 @default.
• W3046711385 cites W2795450505 @default.
• W3046711385 cites W2800369200 @default.
• W3046711385 cites W2802736852 @default.
• W3046711385 cites W2807553755 @default.
• W3046711385 cites W2810462336 @default.
• W3046711385 cites W2811398514 @default.
• W3046711385 cites W2888080853 @default.
• W3046711385 cites W2897110761 @default.
• W3046711385 cites W2900809836 @default.
• W3046711385 cites W2907484695 @default.
• W3046711385 cites W2927686296 @default.
• W3046711385 cites W2944757554 @default.
• W3046711385 cites W2945212476 @default.
• W3046711385 cites W2959332242 @default.
• W3046711385 cites W2965549245 @default.
• W3046711385 cites W2972058749 @default.
• W3046711385 cites W3009204580 @default.
• W3046711385 cites W3012240835 @default.
• W3046711385 cites W3024053676 @default.
• W3046711385 cites W3026032531 @default.
• W3046711385 cites W834578082 @default.
• W3046711385 doi "https://doi.org/10.1016/j.phymed.2020.153298" @default.
• W3046711385 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7395646" @default.
• W3046711385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32781391" @default.
• W3046711385 hasPublicationYear "2020" @default.
• W3046711385 type Work @default.
• W3046711385 sameAs 3046711385 @default.
• W3046711385 citedByCount "58" @default.
• W3046711385 countsByYear W30467113852021 @default.
• W3046711385 countsByYear W30467113852022 @default.
• W3046711385 countsByYear W30467113852023 @default.
• W3046711385 crossrefType "journal-article" @default.
• W3046711385 hasAuthorship W3046711385A5013337556 @default.
• W3046711385 hasAuthorship W3046711385A5049280812 @default.
• W3046711385 hasAuthorship W3046711385A5053877940 @default.
• W3046711385 hasAuthorship W3046711385A5056555947 @default.
• W3046711385 hasAuthorship W3046711385A5075729887 @default.
• W3046711385 hasBestOaLocation W30467113851 @default.
• W3046711385 hasConcept C126322002 @default.
• W3046711385 hasConcept C142724271 @default.
• W3046711385 hasConcept C150903083 @default.
• W3046711385 hasConcept C189165786 @default.
• W3046711385 hasConcept C207001950 @default.
• W3046711385 hasConcept C207865475 @default.
• W3046711385 hasConcept C26291073 @default.
• W3046711385 hasConcept C2776232574 @default.
• W3046711385 hasConcept C2776694085 @default.
• W3046711385 hasConcept C2777714996 @default.
• W3046711385 hasConcept C2778341716 @default.
• W3046711385 hasConcept C2779832356 @default.
• W3046711385 hasConcept C2780171596 @default.
• W3046711385 hasConcept C2780559512 @default.
• W3046711385 hasConcept C2781244666 @default.
• W3046711385 hasConcept C502942594 @default.
• W3046711385 hasConcept C71924100 @default.
• W3046711385 hasConcept C86803240 @default.
• W3046711385 hasConcept C95444343 @default.
• W3046711385 hasConcept C98274493 @default.
• W3046711385 hasConceptScore W3046711385C126322002 @default.
• W3046711385 hasConceptScore W3046711385C142724271 @default.
• W3046711385 hasConceptScore W3046711385C150903083 @default.

• next